[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645740":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":45,"centralContacts":49,"locations":54,"responsibleParty":118,"collaborators":11,"id":120,"slug":121,"hasResults":122,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":122,"sex":128,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":11,"studyType":134,"phases":135,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":57,"whyStopped":11,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},{"fullName":5,"class":6},"Maze Therapeutics","INDUSTRY",[8,14,19,22,25,28],{"label":9,"type":10,"description":11,"interventionNames":12},"MZE782 Low Dose (Cohort 1A)","EXPERIMENTAL",null,[13],"Drug: MZE782",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo (Cohort 1A)","PLACEBO_COMPARATOR",[18],"Other: Placebo",{"label":20,"type":10,"description":11,"interventionNames":21},"MZE782 High Dose (Cohort 1B)",[13],{"label":23,"type":16,"description":11,"interventionNames":24},"Placebo (Cohort 1B)",[18],{"label":26,"type":10,"description":11,"interventionNames":27},"MZE782 High Dose (Cohort 2)",[13],{"label":29,"type":16,"description":11,"interventionNames":30},"Placebo (Cohort 2)",[18],[32,37,42],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":11},"DRUG","MZE782","Tablet, Low Dose",[9],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":11},"OTHER","Placebo","Tablet",[15,23,29],{"type":33,"name":34,"description":43,"armGroupLabels":44,"otherNames":11},"Tablet, High Dose",[20,26],[46],{"name":47,"affiliation":5,"role":48},"Medical Director","STUDY_DIRECTOR",[50],{"name":5,"role":51,"phone":52,"phoneExt":11,"email":53},"CONTACT","650-850-5075","medicalinfo@mazetx.com",[55,69,78,88,98,108],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":11},"UCSF Benioff Children's Hospital Oakland","RECRUITING","Oakland","California","94609","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-122.2708,37.80437,{"lat":67,"lon":66},{"facility":70,"status":57,"city":71,"state":59,"zip":72,"country":61,"countryCode":62,"cosmosGeoPoint":73,"geoPoint":77,"contacts":11},"Stanford University Clinical and Translational Research Unit","Palo Alto","94304",{"type":64,"coordinates":74},[75,76],-122.14302,37.44188,{"lat":76,"lon":75},{"facility":79,"status":57,"city":80,"state":81,"zip":82,"country":61,"countryCode":62,"cosmosGeoPoint":83,"geoPoint":87,"contacts":11},"Indiana University School of Medicine","Indianapolis","Indiana","46202",{"type":64,"coordinates":84},[85,86],-86.15804,39.76838,{"lat":86,"lon":85},{"facility":89,"status":57,"city":90,"state":91,"zip":92,"country":61,"countryCode":62,"cosmosGeoPoint":93,"geoPoint":97,"contacts":11},"University of Kentucky Medical Center","Lexington","Kentucky","40536",{"type":64,"coordinates":94},[95,96],-84.47772,37.98869,{"lat":96,"lon":95},{"facility":99,"status":57,"city":100,"state":101,"zip":102,"country":61,"countryCode":62,"cosmosGeoPoint":103,"geoPoint":107,"contacts":11},"Clinic for Special Children","Gordonville","Pennsylvania","17529",{"type":64,"coordinates":104},[105,106],-76.13357,40.0201,{"lat":106,"lon":105},{"facility":109,"status":57,"city":110,"state":111,"zip":112,"country":61,"countryCode":62,"cosmosGeoPoint":113,"geoPoint":117,"contacts":11},"University of Tennessee Health Science Center Le Bonheur Children's Hospital","Memphis","Tennessee","38103",{"type":64,"coordinates":114},[115,116],-90.04898,35.14953,{"lat":116,"lon":115},{"type":119,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100645740","phase-2-a-study-of-mze782-in-adults-with-pku-100645740",false,"NCT07694440","A Study of MZE782 in Adults With PKU","A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Efficacy of MZE782 in Adults With Phenylketonuria (PKU)","CIPheR","Key Inclusion Criteria:\n\n* Males and females 18 to 75 years old\n* Clinical diagnosis of PKU\n* Willing and able to keep diet and protein intake consistent during the study\n* For some study groups, is willing and able to stop certain PKU medications before starting study treatment\n* For some study groups, may need to meet additional blood phenylalanine level or background-treatment requirements\n* Meets minimum blood phenylalanine level requirements for study group\n\nKey Exclusion Criteria:\n\n* Is pregnant, breastfeeding, or planning to become pregnant or conceive a child during the study or within 90 days after the last dose\n* Medical conditions or abnormal test results that could make participation unsafe or make it difficult to complete study procedures or interpret study results\n* Has recently received another investigational drug\n* Is unable to swallow tablets or tolerate oral medication\n\nOther inclusion\u002Fexclusion criteria defined in protocol apply.","ALL","18 Years","75 Years",{"count":132,"type":133},38,"ESTIMATED","INTERVENTIONAL",[136],"PHASE2","The purpose of this study is to evaluate the safety, tolerability, and efficacy of MZE782 in adults with Phenylketonuria (PKU).",[139],"Phenylketonuria (PKU)",[141,142],"PKU","Phenylketonuria","2026-08-18",{"date":145,"type":146},"2026-08-20","ACTUAL",{"date":148,"type":146},"2026-06-23",{"date":150,"type":133},"2028-02",{"name":5,"class":6},6]